Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab plus CHOP vs two-dose regimens in previously untreated follicular lymphoma (Phase 2)
2007-000244-27Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ofatumumab in follicular lymphoma (FL) and mature B-cell lymphoma (2 arms), sponsored by GSK. Primary endpoint: Objective Response Rate. Started Mar 2007; status: completed.
02
Drugs
ofatumumab
03
Conditions
follicular lymphoma (FL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2007-000244-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000244-27.